Article
Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.
JCI insight - 8 Jun 2022
Yuan Bo, Clowers Michael J, Velasco Walter V, Peng Stephen, Peng Qian, Shi Yewen, Ramos-Castaneda Marco, Zarghooni Melody, Yang Shuanying, Babcock Rachel L, Chang Seon Hee, Heymach John V, Zhang Jianjun, Ostrin Edwin J, Watowich Stephanie S, Kadara Humam, Moghaddam Seyed Javad
Abstract excerpt
K-ras-mutant lung adenocarcinoma (KM-LUAD) is associated with abysmal prognosis and is tightly linked to tumor-promoting inflammation. A human mAb, canakinumab, targeting the proinflammatory cytokine IL-1β, significantly decreased the risk of lung cancer in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study. Interestingly, we found high levels of IL-1β in the lungs of mice with K-rasG12D-mutant tumors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.